Key points are not available for this paper at this time.
Bi-layer tablet technologies is an upgraded advantageous technology that overcomes the disadvantages of the single - layer tablet. The development of pre-determined active ingredient sustained release and the inclusion of incompatible active pharmaceutical ingredients into a single unit dosage form have both been made possible through the availability of bi layer tablets to the pharmaceutical industry. One of the key design strategies for combining incompatible drugs with various indications and the same drug with a varying release rate is provided by bi layer tablets. A bi-layer tablet is appropriate for the combination of sequential release of two drugs as well as Sustained release of a tablet, wherein the first layer is for Immediate release as a loading dosage and the second layer is a maintenance dose. The best choice for drugs with low bioavailability and brief plasma half-lives is to formulate them as bi layer tablets for sustained release. Bi-layer tablets may be the best alternative to prevent physical separation from developing chemical incompatibilities across APIs and to allow for the development of many different profiles for drug release. Bi-layer tablets are currently being developed by several pharmaceutical companies for a variety of purposes, including patent extension, therapeutic use, and marketing, to name a few. As a result, the use of bi-layer tablet for analgesic, anti-inflammatory, and antihypertensive drugs is significantly different. To develop an innovative bi-layer tablet, a comprehensive mechanistic understanding must be developed through the use of dependable, analytical methods for risk management.
Pagar et al. (Sat,) studied this question.